Thursday, 9 February 2012, 9.30 am - 11.00 am CET

SIX Swiss Exchange, ConventionPoint, Auditorium, Selnaustrasse 30, Zurich, Switzerland.

RSVP to Patricia Dal Pont, +41 43 211 42 14, patricia.dalpont@nobelbiocare.com.

This presentation will be audio-webcast live at www.nobelbiocare.com/investors and is also accessible via telephone conference. For the telephone conference, please dial in 10-15 minutes prior to the scheduled start using the following numbers (live-access to speakers for questions after the presentation):

  • +41 (0)91 610 56 00 Continental Europe

  • +44 (0)203 059 58 62 UK

  • +1 (1)866 291 41 66 USA

For additional local dial-in numbers please refer to the separate list:

Additional dial-in nos.

Recording of the webcast will be available on the website shortly after the end of the conference.

The Full Year Results 2011 of Nobel Biocare will be published on 9 February 2012, at around 6.45 am CET.

Investor contact
Name: Süha Demokan (Head of Investor Relations )
Tel: +41 43 211 42 30; +41 79 430 81 46
E-mail:suha.demokan@nobelbiocare.com

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth to root, for single tooth to completely edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive™, Brånemark System® and NobelReplace®), individualized prosthetics and equipment (NobelProcera™), guided surgerysolutions and biomaterials. Nobel Biocare has more than 2,400 employees and recorded revenue of EUR 576.6 million in 2010. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations.

Disclaimer
This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.